This is a phase 2, prospective, multicenter, randomized, double blind, placebo controlled,
parallel group study to evaluate the safety and efficacy of intravenous (IV) administration
of CSL324, administered in combination with SOC treatment, in subjects with COVID 19.
For the purposes of this study, standard of care (SOC) may include any written or established
treatment protocol followed at the study site for the treatment of severe COVID-19 or its
complications, including off-label use of marketed pharmaceutical products and / or products
with emergency use authorization granted for the treatment of COVID-19 (ie, not yet marketed)
(eg, remdesivir).